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Abstract
 
The impact of HIV-associated immunopathogenesis on B cells has been largely associated with
indirect consequences of viral replication. This study demonstrates that HIV interacts directly
with B cells in both lymphoid tissues and peripheral blood. B cells isolated from lymph node
and peripheral blood mononuclear cells (PBMCs) of 4 and 23 chronically infected patients, re-
spectively, demonstrated similar capacities to pass virus to activated HIV-negative PBMCs
 
when compared with CD4
 
1
 
 cells from the same patients. However, in contrast to T cells, virus
associated with B cells was surface bound, as shown by its sensitivity to pronase and the staining
pattern revealed by in situ amplification of HIV-1 RNA. Cell sorting and ligand displacing ap-
proaches established that CD21 was the HIV-binding receptor on B cells, and that this associa-
tion was mediated through complement-opsonized virus. These B cells were also found to ex-
press significantly lower levels of CD21 compared with HIV-negative individuals, suggesting a
direct perturbing effect of HIV on B cells. These findings suggest that B cells, although they
themselves are not readily infected by HIV, are similar to follicular dendritic cells in their ca-
pacity to serve as extracellular reservoirs for HIV-1. Furthermore, B cells possess the added ca-
pability of circulating in peripheral blood and migrating through tissues where they can poten-
tially interact with and pass virus to T cells.
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Introduction
 
HIV-1 replicates predominantly in activated CD4
 
1
 
 T cells.
However, numerous other cell types contribute to HIV in-
fection by acting as reservoirs or carriers for the virus. In-
tracellular reservoirs of HIV that have been well described
include macrophages and latently infected resting CD4
 
1
 
 T
cells, and extracellular sources of virus include dendritic
 
cells (DCs)
 
1
 
 and follicular dendritic cells (FDCs; for review
see references 1–3). Recently, the HIV capturing and
transporting properties of DCs have been clarified with the
identification of DC-SIGN, a lectin-based membrane pro-
tein that is uniquely expressed on DCs and demonstrates a
specific capacity to interact with HIV envelope (4). Direct
binding and stabilization of virions on cells that are not sus-
ceptible to infection have also been proposed to involve in-
teractions between integrins expressed on the cell surface
and adhesion molecules acquired by HIV-1 (5). In contrast,
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the demonstration of HIV-trapping on FDCs has relied on
ultrastructural analyses of germinal center sections stained
for gag proteins or HIV-RNA (6–8), and in vitro
 
 
 
reconsti-
tution of HIV trapping on FDCs via immune complexes
(ICs; 9, 10).
HIV-mediated perturbations of B cell functions have
been well described (11, 12) and are largely thought to re-
flect indirect effects of HIV replication. Several direct in-
teractions between HIV and B cells have been suggested
from in vitro studies, (for review see references 13, 14), yet
in vivo correlates of these observations are lacking. Fur-
thermore, perturbations of B cell function resulting from
direct HIV infection of B cells have been suggested from
numerous in vitro studies (15, 16); however, few in vivo
correlates have been identified.
It has been suggested that one of the major modes of in-
teraction between HIV and FDCs in vivo involves binding
of HIV IC to complement receptors expressed on FDCs
(9). Interestingly, B cells also express complement recep-
tors, traffic through follicles where HIV RNA signal is
most intense (17, 18), migrate to the periphery of follicles
for interaction with T cells (19), and bind HIV in vitro
through IC–CD21 interactions (20). In this study, we
demonstrate that replication-competent virus binds directly
to B cells isolated from lymphoid tissues and/or peripheral
blood of patients chronically infected with HIV-1. This
phenomenon was consistently demonstrated in chronically
infected patients who have plasma viral loads 
 
.
 
10,000 cop-
ies of HIV RNA per ml. By cell sorting, virus displacing,
and complement-based capture assays we demonstrate that
the association between HIV and B cells occurs through
interactions between CD21 expressed on the surface of B
cells and C3 fragments bound to HIV particles.
 
Materials and Methods
 
Study Subjects.
 
23 HIV-1–infected patients were studied; 19
were chronically viremic and 4 were recently viremic after inter-
ruption of antiretroviral therapy that previously had suppressed
viremia successfully (21). Of the 19 chronically viremic individu-
als studied, patients 4, 7, 16, and 17 were antiretroviral drug na-
ive, and the remaining patients were either not fully compliant
with their antiretroviral regimens or were failing therapy, thus
explaining the presence of detectable viremia. All protocols were
carried out in accordance to the Institutional Review Board of
the National Institute of Allergy and Infectious Diseases.
 
Antibodies.
 
FITC- or PE-conjugated mAbs specific for
CD19, CD20, CD21, CD3, and CD14 were purchased from
Becton Dickinson, and, in the case of CD4, CD1a, IgM, IgG,
and CD32, from BD PharMingen. The C3-displacing anti-CD21
mAb FE8 was provided by Dr. W.M. Prodinger (University of
Innsbruck, Innsbruck, Austria). The negative control, isotype-
matched anti-CD21 mAb BL13, was purchased from Beckman
Coulter. Rabbit anti–human C3d antibody, which recognizes na-
tive C3, C3b, iC3b, C3d, and C3dg, was purchased from Dako.
Normal rabbit serum was obtained from Caltag Laboratories.
 
Cell Preparations.
 
PBMCs were obtained from lymphophere-
sis or standard blood draws by Ficoll-Hypaque density gradient
centrifugation. Excisional inguinal lymph node biopsies were
performed on a subset of patients to obtain lymph node mononu-
 
clear cells (LNMCs). LNMCs were obtained by gentle mechani-
cal manipulation of the tissue. B cells were isolated by negative
selection using a column-based purification technique (StemCell
Technologies). Purity of B cell preparations was verified by flow
cytometry (EPICS XL Flow cytometer; Beckman Coulter), with
a panel of mAbs against CD19, CD20, and CD21. Typically
these markers accounted for 
 
.
 
95% percent of the cell suspen-
sions, with the remainder of the cells expressing neither CD14
nor CD1a, nor coexpressing CD3 and CD4. CD4
 
1
 
 T cell popu-
lations were prepared by depleting PBMCs or LNMCs of CD8
 
1
 
cells by magnetic bead depletion (Dynal); CD19
 
1
 
 cells were also
removed for the data collected from patient 2 in Fig. 1 and all
patients in Table I (see below).
 
HIV-1 Quantitation, Visualization, and Phenotyping Assays.
 
The
number of copies of HIV-1 RNA was determined in each cell
preparation by a nucleic acid sequence–based amplification
(NASBA) technique, using an established protocol (22). The
limit of detection of the assay varied between 40 and 80 copies of
HIV RNA. For the in situ NASBA, cells were fixed (Permea-
fix™; Ortho Diagnostic Systems), cytospun onto silianated slides
at a concentration of 5 
 
3
 
 10
 
4
 
 cells per slide, and air-dried. The
HIV NASBA reaction was carried out at 41
 
8
 
C for 2 h in the pres-
ence of an FITC-labeled probe that recognizes two separate areas
of the amplified product and induces form concatamers. After the
NASBA reaction, slides were washed and stained for DNA with
DAPI (Sigma-Aldrich), according to the recommendations of the
manufacturer. Images of the stained cells were acquired by confo-
cal microscopy.
Replication-competent virus associated with each cell prepara-
tion was evaluated by coculturing 10
 
6
 
 cells with 10
 
6
 
 anti-CD3
stimulated HIV-negative PBMCs depleted of CD8
 
1
 
 T cells (in-
dicator T cells). Surface-bound virus was removed by pronase
(Roche Molecular Biochemicals) pretreatments as previously de-
scribed (23), with the modification that 20 mg/ml of pronase was
used in the assay. Productive infection was evaluated by ELISA
determination of HIV-1 p24 (Beckman Coulter). Virus collected
at the peak of replication in cocultures was analyzed for corecep-
tor usage by exposure to the human glioma cell lines U87/CD4
expressing the chemokine receptors CCR5 or CXCR4 (pro-
vided by D.R. Littman, New York University Medical Center,
New York, NY).
 
B Cell Subset and Ligand-displacing Analyses.
 
Fresh or thawed
PBMCs from HIV-infected individuals were depleted of CD2-
and CD14-expressing cells using magnetic bead separation proto-
cols, then sorted on a EPICS ELITE cell sorter (Coulter) into
one of the following subset pairs: CD20
 
1
 
/CD21
 
1
 
 and CD20
 
1
 
/
CD21
 
2
 
 or CD20
 
1
 
/CD32
 
1
 
 and CD20
 
1
 
/CD32
 
2
 
. In other exper-
iments, B cells prepared by negative selection (StemCell Tech-
nologies) were depleted of surface IgG– or surface IgM–express-
ing cells by incubation with biotinylated anti-IgG or anti-IgM
antibodies (BD PharMingen), followed by incubation with
streptavidin-conjugated magnetic beads (Dynal) and separation
on a magnet. Subsets of B cells were tested for the presence of
replication-competent HIV by coculturing equal numbers of B
cells from each fraction with indicator T cells. For displacement
of HIV-bound C3 fragments, B cells were isolated from PBMCs
of HIV-infected patients by negative selection. The cells were in-
cubated with 2 
 
m
 
g/ml of anti-CD21 C3 fragment–displacing
mAb FE8 or control anti-CD21 mAb BL13 for 1 h at 37
 
8
 
C,
washed once, incubated a second time with 2 
 
m
 
g/ml mAb for 30
min at 37
 
8
 
C, washed twice, and cocultured with indicator T
cells. HIV virions displaced by FE8 were captured by sequential
incubations with rabbit anti-C3d antibodies and sheep anti–rab- 
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bit–conjugated magnetic beads (Dynal), followed by separation of
unbound virions by magnetic bead separation. Levels of HIV
RNA in each fraction, including samples of FE8-displaced virus
incubated with normal heat-inactivated rabbit serum (negative
control), were determined by branched DNA assay (limit of de-
tection, 50 copies of HIV-1 RNA; Chiron Corp.).
 
Results and Discussion
 
Association of HIV-1 with Tissue- and Blood-derived B Cells
Isolated from Chronically Infected Patients.
 
We have previ-
ously reported that B cells are susceptible to CD4/
CXCR4-dependent HIV-1 infection in vitro (24). To de-
termine whether B cells are productively infected in vivo,
we initially analyzed cultures of B cells derived from PB-
MCs of several HIV-1–infected patients. While there was
little evidence of productive replication under these condi-
tions, we found substantial amounts of HIV-1 RNA associ-
ated with freshly isolated LNMC- and PBMC-derived B
cells of chronically infected patients harboring either R5 or
X4 virus (see Fig. 1 A and Table I for virus phenotypes). In
agreement with previous studies, the levels of HIV RNA
detected in each LNMC and LNMC-derived B cell sample
were 5- to 15-fold higher than their corresponding PBMC
samples (17, 18), with the exception of levels from patient
2, who had similar levels of HIV RNA in both LMNC-
and PBMC-derived B cells. The replication capacity of vi-
rus associated with each cell preparation for three of the
four patients was also investigated by micro coculture anal-
ysis with anti-CD3 activated, CD8-depleted PBMCs from
HIV-negative donors (referred to as indicator T cells). Un-
der these conditions, all sources of B cells were found to
harbor replication-competent virus (Fig. 1 B), the kinetics
of which reflected the differences in cellular HIV RNA.
Conversely, the high copy number of HIV RNA detected
in unfractionated LNMC samples did not lead to corre-
spondingly high levels of replication-competent virus in
the cocultures. This probably was due to mechanical dis-
ruption and loss of FDC-trapped HIV particles, the form of
virus thought to account for the majority of HIV RNA
signal in lymphoid tissues (17, 18). Interestingly, patient 2,
who had a peripheral blood lymphocyte composition of 1%
CD4
 
1
 
 T cells and 47% CD19 B cells (Table I), had higher
levels of replication-competent virus per input cell associ-
ated with his PBMC-derived B cells than with his corre-
sponding CD4
 
1
 
 T cells (1477 vs. 647 ng/ml p24; Fig. 1 B).
Taken together, these data underscore the importance of
the B cells of this patient as a reservoir of extracellular HIV.
 
Detailed Characterization of B Cell–associated HIV-1 in the
Peripheral Blood of Chronically Infected Patients.
 
To estab-
lish the scope of patients whose B cells harbor HIV, we
performed in depth analyses of peripheral blood B cells iso-
lated from 19 chronically viremic patients (Table I, patients
1–19) and 4 recently viremic patients (Table I, patients 20–
23). A parallel CD4
 
1
 
 T cell fraction was prepared from
each patient studied by depleting PBMCs of CD8 and
CD19 cells. For all patients studied, the level of HIV RNA
associated with each cell fraction lysate was determined by
NASBA analysis (Table I). The B cell–associated HIV-1
RNA levels ranged from undetectable to 1,700 copies/10
 
5
 
cells (median: 460 copies/10
 
5
 
 cells), whereas T cell–associ-
ated HIV-1 RNA ranged from undetectable to 8,100 cop-
ies/10
 
5
 
 cells (median: 2,000 copies/10
 
5
 
 cells). The mean ra-
tio of HIV RNA between B and CD4
 
1
 
 T cells was 0.23.
To establish the cellular localization of the HIV RNA sig-
nal, we performed a qualitative in situ NASBA analysis for
HIV-1 
 
gag
 
 sequences. The B cell–associated HIV-1 RNA
localized to the surface of the cells, as suggested by the
staining pattern that was largely restricted to the periphery
of the cells (Fig. 2, A and B) and reduction of staining to
background level (Fig. 2 E) when cells were treated with
pronase before NASBA (data not shown). In contrast, the
T cell–associated HIV-1 RNA was found to be dispersed
throughout the cytoplasm (Fig. 2, C and D) and largely in-
Figure 1. Levels of cell-associated HIV-1 RNA and replication-com-
petent virus in various cell types isolated from patients chronically in-
fected with HIV-1. Highly enriched B cells identified as LNMC-B and
PBMC-B were isolated from LNMCs and PBMCs, respectively, of (A)
four patients and compared with corresponding unfractionated cells for
levels of cellular HIV RNA, and (B) in three patients compared with cor-
responding CD8-depleted cells for levels of replication-competent virus.
Coculture conditions included 106 HIV-infected cells and 106 indicator T
cells, with the exception of LNMCs of patient 6, where cocultures were
performed on 0.2 3 106 input cells. Levels of HIV-1 p24 were measured
in coculture supernatants on day 7. 
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sensitive to pronase treatment (data not shown). Varying
degrees of brightness were observed throughout the B cell
population (Fig. 2 A), ranging from rare bright green ring-
like patterns to dimmer specks of green on the contour of
the cells, indicated by arrows. This spectrum of HIV RNA
staining could also be observed at higher magnification for
a single B cell (Fig. 2 B), contrasting sharply with the dense
intracellular staining associated with T cells (Fig. 2 D).
These data suggest a nonuniform mode of interaction be-
tween HIV particles and B cells through molecules that are
either unevenly expressed or vary in binding affinities.
To evaluate the replication capacity of the HIV RNA
measured in each PMBC subset, B and CD4
 
1
 
 T cell prep-
arations were cocultured with indicator T cells, as de-
scribed for Fig. 1. As shown in Table I, all 23 chronically
and recently viremic patients had replication-competent vi-
rus associated with their B cells. The kinetics of virus pas-
sage generally correlated with the levels of HIV RNA de-
tected in the B cells; however, other factors, including
virus phenotype, were found to affect replication kinetics.
Repeat analysis of several patients whose viral loads fluctu-
ated over the course of the study revealed that levels of B
cell–associated but not T cell–associated virus closely paral-
leled changes in plasma viremia (data not shown), support-
 
Table I.
 
Profiles of HIV-1–infected Patients with Capacity of B Cells to Bind Replication-competent Virus
 
T cell–associated virus B cell–associated virus
Patient CD4 CD19
CD21
 
2
 
B Cells
 
*
 
Plasma
viral load
 
‡
 
HIV-1
RNA
 
§
 
Passage
 
i
 
Phenotype
 
¶
 
HIV-1
RNA
 
§
 
Passage
 
i
 
Phenotype
 
¶
 
per 
 
m
 
l% %
copies
per ml
 
1 5 22 12 1,025,830 8,100 Rapid/high X4 
 
. 
 
R5 630 Mod/med X4 
 
. 
 
R5
2 6 47 20 194,638 670 Rapid/high R5, X4 830 Rapid/high R5, X4
3 7 76 ND 115,511 4,900
 
**
 
Rapid/high R5 
 
.
 
 X4 450 Mod/med R5 
 
.
 
 X4
4 8 14 ND 76,838 2,000 Rapid/high X4 370 Rapid/high X4
5 48 15 ND 169,014 1,900 Rapid/high R5 140 Mod/med R5
6 85 15 50 14,513 5,500 Rapid/high X4 
 
. 
 
R5 1,200 Rapid/med R5
7 89 9 ND 1,105,380 7,800
 
**
 
Rapid/high X4 
 
. 
 
R5 1,300 Rapid/high X4 
 
. 
 
R5
8 92 12 23 16,989 540 Rapid/high X4 
 
. 
 
R5 140 Rapid/high X4 
 
. 
 
R5
9 108 10 8 133,822 4,400 Mod/med R5 1,700 Mod/med R5
10 114 20 42 58,211 1,200 Rapid/high X4 
 
@ 
 
R5
 
,
 
LDL Slow/high X4 
 
@
 
 R5
11 135 10 30 37,606 420 Mod/high X4, R5 100 Slow/high X4 
 
. 
 
R5
12 188 7 41 249,966 ND Rapid/high R5 ND Mod/high R5
13 202 21 38 11,232 2,600 Rapid/med R5 460 Rapid/med R5
14 227 16 37 176,481 5,500 Rapid/high X4 1,300 Rapid/med X4
15 350 13 28 41,183 2,400 Rapid/high R5 460 Mod/high R5
16 390 11 75 31,335 1,200 Mod/med R5 210 Mod/low R5
17 483 9 33 100,730 1,500 Rapid/high R5 470 Mod/high R5
18 542 15 39 217,208 1,800 Rapid/high R5 470 Mod/high R5
19 987 22 7 62,743 3,500 Slow/med R5 1,700 Mod/med R5
20
 
‡‡
 
316 5 44 166,143 4,200 Rapid/high R5 1,400 Mod/high R5
21
 
‡‡
 
562 3 32 89,442 300 Slow/high R5 140 Slow/high R5
22
 
‡‡
 
1,177 9 18 254,150 640 Slow/high R5 310 Mod/high R5
23
 
‡‡
 
1,573 3 ND 109,850
 
,
 
LDL Mod/high R5 100 Mod/high R5
ND, not done; 
 
,
 
LDL, below limit of detection.
 
*
 
Percentage of CD20
 
1
 
 cells that are CD21
 
2
 
.
 
‡
 
Measured by reverse transcriptase PCR.
 
§
 
Measured by NASBA, copies/10
 
5
 
 cells.
 
i
 
Kinetics of passage from B or T cell preparations to indicator T cells, evaluated periodically by p24 release in culture supernatant. Rapid, p24
 
1
 
(
 
.
 
100 pg/ml) by day 3; Mod, p24
 
1
 
 between days 4 and 6; Slow, p24
 
1
 
 after day 6; High, peak p24 
 
.
 
100 ng/ml; Med, peak p24 between 10 and
100 ng/ml; Low, peak p24 
 
,
 
10 ng/ml.
 
¶
 
Coreceptor usage of isolated virus was evaluated on U87-CD4-X4 and U87-CD4-R5 cell lines.
 
**
 
Measured on unfractionated PBMCs.
 
‡‡
 
Samples taken at 4–5 wk after interruption of antiretroviral therapy. 
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ing the notion of extracellular interactions between B cells
and HIV virions. Furthermore, the replication-competent
virus found on the surface of B cells of recently viremic pa-
tients (Table I, patients 20–23) also suggests that the associ-
ation between HIV and B cells is readily reestablished
when the virus is rebounding after discontinuation of anti-
retroviral therapy after prolonged suppression of viremia.
Sensitivity of B and T Cell–associated HIV to Proteolytic
Treatment of Cell Surfaces. Inter-patient comparison of the
capacities of B and T cells to pass virus to indicator T cells
(B–T and T–T respectively) revealed that, overall, passage
of virus was more efficient in T–T than B–T cocultures.
However, the kinetics of passage of virus from input B cells
to indicator T cells were surprisingly rapid considering the
fivefold difference in RNA levels between CD41 T cells
and B cells. Based on these observations and the location of
the pronase-sensitive RNA signal revealed by in situ
NASBA (Fig. 2), we hypothesized that the HIV RNA de-
tected on B cells represented readily available and infec-
tious viral particles, whereas the signal in the T cells repre-
sented genomic or messenger RNA. To directly test this
hypothesis, B and T cell suspensions from eight of the pa-
tients described in Table I were treated with pronase before
cocultivation. In all eight patients, as shown by three repre-
sentative graphs in Fig. 3 A, proteolysis completely abro-
gated the passage of virus from the B cells to the indicator
T cells, whereas the CD41 T cell preparations were unaf-
fected by pronase treatment. In seven out of eight patients a
dramatic decrease in the levels of B cell–associated HIV-1
RNA, but not T cell–associated HIV-1 RNA as measured
by NASBA, was also observed after pronase treatment (data
not shown). Taken together, these data strongly suggest
that the HIV-1 RNA associated with B cells of chronically
HIV-1–infected patients is in the form of surface-bound
virions that can readily initiate a spreading infection when
placed in proximity to activated CD41 T cell targets. Con-
versely, the HIV-1 RNA associated with T cells largely re-
flects pronase-insensitive intracellular HIV-1 RNA.
Virus Phenotypes Associated with B Cells In Vivo. Re-
cently, we reported that X4 strains of HIV-1 can infect
CD40-activated B cells in vitro through CD4–CXCR4 in-
teractions, whereas a lack of CCR5 expression on these
cells explains their resistance to R5 strains (24). In this
study, we found that the majority of the virus associated
with B cells of HIV-infected patients did not replicate
when, in the absence of indicator T cells, the B cells were
cultured under stimulatory conditions involving CD40
ligand, LPS, or the phorbol ester PDBu (data not shown).
The reasons for the apparent discrepancy with our previous
in vitro findings may be explained by difficulties in repro-
ducing an in vivo environment in an in vitro setting, espe-
cially considering the low and variable expression of CD4
on B cells (25). Alternatively, and more likely, B cells may
not be targets for productive HIV infection in vivo. Fur-
thermore, we isolated both X4 and R5 viruses from the B
cells of HIV-infected patients (Table I), and with the ex-
ception of patient 6 no detectable differences in coreceptor
usage were observed between viruses recovered from the B
cell and CD41 T cell fractions (Table I). Since CCR5 ex-
pression on B cells is generally undetectable (26), and no
R5-using HIV-1 has been found to infect primary B lym-
phocytes (24), these data suggest that B cells bind HIV in
vivo by a mechanism that is independent of CD4 and
chemokine receptors.
Mechanism of Interaction between HIV and B Cells. To
investigate the mechanism of interaction between HIV and
B cells in vivo, we performed extensive B cell subset analy-
ses using surface markers that have been associated with
HIV binding to B cells in vitro (20, 27, 28), and/or with
trapping of immune-complexed virus by FDCs in vivo (8–
10). Accordingly, binding to HIV envelope–specific surface
Ig was addressed by depleting the surface IgG– and IgM–
expressing B cells of patients 8, 11, and 19; virus was passed
to indicator T cells with kinetics similar to those described
in Table I (data not shown). The possibility that HIV binds
Figure 2. Location of HIV RNA in and on cells isolated from an HIV-
infected individual. In situ amplification for HIV-1 RNA (gag) was car-
ried out on highly purified B cells from patient 9 (A and B), CD8/CD19-
depleted PBMCs from patient 9 (C and D), and HIV-negative PBMCs
(E). The FITC stains (HIV RNA, in green) were overlaid onto the corre-
sponding DAPI stains (cellular DNA, in red) to create the final image. Ar-
rows indicate where weak positive signals were observed on the surface of
B cells. Original magnification: (A, C, and E) 3400; (B and D) 31,000.642 Complement-complexed HIV-1 Binds CD21 on B Cells
Figure 3. Characterization of the replication-competent virus associated with PBMC-derived B cells of HIV-infected patients. (A) B cells and T cells
isolated from three HIV-infected individuals were pretreated with pronase followed by coculture with indicator T cells. (B, top) Flow cytometric com-
parison of CD21 expression on representative HIV-negative B cells and presorted B cells of patient 17, followed by (B, bottom) post-sorted CD201/
CD211 and CD201/CD212 fractions of patient 17. (C) B cells of three HIV-infected patients sorted into CD211 and CD212 fractions (and CD321 ver-
sus CD322 fractions in the case of patient 19) and cocultured with indicator T cells. For patients 11 and 17, shade of symbol identifies the sorted fraction
and shape of symbol identifies the number of coculture wells plated for a given sorted fraction. (D) Flow cytometric comparison of CD21 (continues)643 Moir et al.
B cells through Fc receptor interactions was addressed by
sorting the B cells of patients 11, 13, and 19 into CD321
and CD322 fractions; virus was passed to indicator T cells
with kinetics similar to those described in Table I; data for
patient 19 are shown in Fig. 3 C. The possibility that HIV
binds B cells through IC–complement receptor interactions
was addressed by sorting the B cells of patients 6, 11, 13,
16, 17, and 19 into CD211 and CD212 fractions (typical
FACS™ staining shown in Fig. 3 B). In all six patients, as
shown by three representative graphs in Fig. 3 C, replica-
tion-competent virus in the CD21-depleted fractions was
either absent or showed dramatically reduced replication
kinetics compared with the CD21-enriched fractions. Fi-
nally, verification of surface markers after pronase treatment
revealed a dramatic suppression of CD21 expression on B
cells of HIV-infected patients (representative data shown in
Fig. 3 D), providing a mechanistic explanation for the ini-
tial observation made in Fig. 3 A on the sensitivity of B
cell–bound virus to pronase. We found no cosegregation of
the CD211 fraction with markers such as surface IgD/G/M
that may be involved in superantigenic binding of HIV en-
velope to VH3 (27) or CD4 (data not shown), suggesting
that HIV-1 preferentially interacts with B cells through IC
binding to CD21. However, there remained the possibility
that HIV binds B cells through another CD21-cosegregat-
ing receptor, such as CD35, or a novel B cell marker.
Displacement of HIV-1 Particles from B Cells with a C3-dis-
placing Anti-CD21 mAb. To directly address the role of
CD21 in HIV binding to B cells, we preincubated the B
cells of six HIV-infected patients with the anti-CD21 mAb
FE8, which has been shown to block and displace the
binding of C3 fragment (C3d/C3dg, iC3b)–coated parti-
cles (29). In parallel, B cells were also preincubated with an
isotype-matched, anti-CD21 mAb BL13, known to bind
outside the ligand-binding domain for C3 fragments (30).
In agreement with the sorting data, pre-incubation with
FE8 but not BL13 either completely abrogated or dramati-
cally reduced the levels of replication-competent HIV asso-
ciated with the B cells of all six patients studied (Fig. 3 E
shows three representative graphs). Furthermore, in order
to demonstrate that the binding of HIV to CD21 was me-
diated by C3 fragments, we performed C3 capture assays
on FE8-displaced virus using rabbit anti–human C3d and
magnetized anti–rabbit IgG antibodies, followed by detec-
tion of HIV-1 RNA in the magnetic bead and soluble frac-
tions. Although a high proportion of FE8-displaced HIV
from the B cells of patients 9, 12, and 18 remained in the
soluble fraction, anti–human C3d antibodies captured sig-
nificant amounts of virus when compared with normal se-
rum (Fig. 3 F). Considering that B cells incubated with the
nondisplacing anti-CD21 mAb BL13 released undetectable
levels of HIV RNA (data not shown), the virus released by
FE8 but not captured by anti-C3d antibodies may repre-
sent a C3-independent mode of binding between HIV and
CD21. Alternatively, virions may have become dissociated
from C3 fragments during the incubation steps with FE8,
or the HIV-C3 fragment association may have partially re-
stricted recognition of the latter by anti-C3d. Nonetheless,
these data confirm that C3 fragments contribute to the
binding of HIV to CD21 on B cells.
This study has several implications for in vivo HIV
pathogenesis, regarding direct effects of HIV on B cell
function, enhancement of virus replication by complement
products, and a potential role for B cells as a reservoir for
HIV-1. CD21 has been directly associated with B cell acti-
vation (31), suggesting that the constant triggering of
CD21 by HIV IC may contribute to the high levels of
polyclonal B cell activation described in HIV disease and
exacerbated when viremia is not controlled by antiretrovi-
ral therapy (32). Of note, CD21 expression on B cells of
HIV-infected patients can be dramatically decreased com-
pared with HIV-negative individuals (Table I and Fig. 3 B;
references 33, 34), suggesting a direct perturbation of B
cells by HIV IC binding. Furthermore, in agreement with
(continued) expression on pronase-treated and -untreated B cells of patient 9. (E) B cells of three HIV-infected patients preincubated with mAbs FE8 and
BL13 and cocultured with indicator T cells. (F) FE8-displaced HIV from 2 3 106 B cells of three HIV-infected patients, treated with rabbit anti–human
C3d (C3d Ab) or normal rabbit serum (Normal Ab), and captured with magnetized anti-rabbit antibodies. Fractions captured on magnet (1 bead) and
fractions not captured (2 bead) were tested for HIV-1 RNA by bDNA.644 Complement-complexed HIV-1 Binds CD21 on B Cells
previous studies on HIV-mediated destruction of lymphoid
tissues that are the major sites of HIV replication (7, 8, 17,
18), we demonstrate that HIV–B cell interactions are am-
plified in lymphoid tissues. Our findings suggest that, simi-
lar to the situation in which HIV trapped on FDCs serves
as a source of infection of CD41 T cells migrating into
lymphoid tissue germinal centers (10), HIV can be pre-
sented to activated CD41 T cell targets as B cell immune-
complexed virus. Furthermore, since B cells circulate
through peripheral blood and migrate within lymphoid tis-
sues to the border of follicles for cognate B–T interactions
(19), they may have even greater opportunities than FDCs
to transmit virus to T cells.
In summary, 23 out of 23 chronically HIV-1–infected
patients with viral loads .10,000 copies of HIV-1 RNA
per ml were found to have replication-competent, pro-
nase-sensitive virus associated with their B cells that was
readily transmitted to activated HIV-negative CD41 T
cells. The CD21-based sorting experiments and the C3-
displacing assays performed on several patients indicate that
HIV-1 interacts directly with B cells through CD21–IC in-
teractions. These findings are underscored by the facts that
a significant portion of virions circulate in the blood as ICs
(35), and complement breakdown products increase with
HIV infection (36). Furthermore, a recent in vitro study
indicates that virions bound to B cells through IC interac-
tions are far more infectious for T cells than are free virions
(20). The role of HIV-specific antibodies in these ICs has
not been addressed here; however, numerous studies sug-
gest their presence contributes to the HIV-enhancing ef-
fects of complement (37–40). Thus, our findings provide
new insights regarding the potential role of B cells as a
unique extracellular reservoir for HIV.
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